MMP9 and melanoma: MMI270 (CGS27023A), a targeting inhibitor of MMP-2, MT1-MMP, and MMP-9 and belonging to the group of nonpeptidomimetic hydroxamate inhibitors, significantly reduced the number of metastatic B16-F10 melanoma colonies in the lungs of mice without affecting colony size, in contrast to the spontaneously metastasizing melanoma line B16-BL6, due to the difference between hematogenous and lymphatic metastasis pathways [127].